In fact, apigenin increases in a dose-dependent way in CRC cells, both in vivo and in vitro, NAG-1 and p53 expression, reducing intestinal tumor load and number (Zhong et al., 2010). This evidence concerns the gene TP53 and colorectal carcinoma.